SOURCE: Stem Cell Therapy International, Inc.

October 24, 2005 06:26 ET

Stem Cell Therapy International Names Dr. Alexey Bersenev, MD., PhD. to Its U.S. Medical and Scientific Advisory Board

TAMPA, FL -- (MARKET WIRE) -- October 24, 2005 -- Stem Cell Therapy International, Inc. (OTC: SCII), a company in the field of research and development of stem cell transplantation therapy and regenerative medicine, today appointed Alexey Bersenev, M.D., Ph.D., who is a research fellow at the Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, to its Scientific Advisory Board.

Dr. Bersenev is conducting stem cell research on leukemia in the Kimmel Cancer Center in the department of microbiology and immunology. Prior to his association with Thomas Jefferson University, he was a senior scientist in the Stem Cell Biotechnology Laboratory of the Institute of Transplantology, Moscow, Russia. He holds an M.D. in surgery and general medicine from the Izhevsk State Medical Institute in Russia and a Ph.D. in Transplantation from the Stem Cell Biotechnology Laboratory, Institute of Transplantology, Moscow, Russia.

Calvin Cao, chairman and chief executive officer of Stem Cell Therapy International, said, "Alexey Bersenev has experience in cell culture and cell transplantation methods, which makes him ideally suited to working with SCTI's Ukrainian medical and scientific advisory board members from Kiev in formulating treatment protocols, research plans, new scientific discoveries in SCT. He is familiar with the majority of clinical trials being conducted in cell therapy around the world and therefore can contribute useful advice on the potential for cell therapy to be successfully developed for a wide range of conditions."

Stem cell transplantation (SCT) therapy is a field of medicine which uses techniques and technologies that rely on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. This therapy is similar to the process of organ transplantation, only the treatment consists of the transplantation of stem cells into the body rather than entire organs, thus eliminating any chance of rejection or the need for expensive and potentially dangerous immunosuppression drug therapy. These new techniques are being applied to finding a cure for a wide range of human disorders, including neurological diseases such as Alzheimer's, Parkinson's Disease, ALS, (also commonly known as Lou Gehrig's disease), leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer and helps alleviate the side effects of chemotherapy.

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion was created to fund stem cell research. Since then four other states, New Jersey, Connecticut, Illinois and Wisconsin, have allocated funds for stem cell research. Among the leading public companies in the U.S. in the field of stem cell technology are Advanced Cell Technology, Inc.; ViaCell; Geron; StemCells, Inc., and Aastrom Biosciences Inc. For additional information on SCTI, please visit our website @ www.scticorp.com.

About Stem Cell Therapy International (SCTI)

Stem Cell Therapy International is in the research and development field of regenerative medicine. SCTI provides stem cell solutions that are currently being used in the treatment of patients suffering from degenerative disorders of the human body. The Company has established agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI intends to provide these biological solutions containing stem cell products in the United States as well, to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials. Their products, which are available for use now, include various biological solutions containing embryonic stem cells, adult stem cells and stem cell which are extracted from umbilical cord blood.

Forward-Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct.

Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.

Contact Information

  • For additional information, please contact:

    Stem Cell Therapy
    International
    Calvin C. Cao
    Chairman and CEO
    Stem Cell Therapy
    International
    T: 813-600-4088
    E: calvin@scticorp.com


    Investor Relations
    Arun Chakraborty
    Investor Relations
    Stern & Co.
    T: 212-888-0044
    E: achakrab@sternco.com

    Media Relations
    Stan Froelich
    VP, Media Relations
    Stern & Co.
    T: 212-888-0044
    E: sfroelich@sternco.com